Nurix Therapeutics, Inc. (NRIX) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "NRIX"
      ],
      "issuer_cik": "0001549595",
      "owner_cik": "0001817160",
      "accession_number": "0001817160-26-000021",
      "form_type": "4",
      "filing_date": "2026-10-15",
      "period_of_report": "2026-10-15",
      "issuer_name": "Nurix Therapeutics, Inc.",
      "issuer_trading_symbol": "NRIX",
      "owner_name": "Hansen Gwenn",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Scientific Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-15",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 1452,
      "transaction_price_per_share": 25,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 117227,
      "transaction_value": 36300,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."
        }
      ]
    },
    {
      "tickers": [
        "NRIX"
      ],
      "issuer_cik": "0001549595",
      "owner_cik": "0001226675",
      "accession_number": "0001226675-26-000006",
      "form_type": "4",
      "filing_date": "2026-10-14",
      "period_of_report": "2026-10-14",
      "issuer_name": "Nurix Therapeutics, Inc.",
      "issuer_trading_symbol": "NRIX",
      "owner_name": "GREGORY JULIA P",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-10-14",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 22583,
      "transaction_price_per_share": 23.4038,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 10750,
      "transaction_value": 528528.0154,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Represents the weighted average sale price. The lowest price at which shares were sold was $23.34 and the highest price at which shares were sold was $23.62. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.